crudeoil24
3 years ago
SEC 424B5 > We have entered into a sales agreement with B. Riley Securities, Inc., Oppenheimer & Co. Inc., and H.C. Wainwright & Co., LLC (collectively the โAgentsโ and each an โAgentโ), relating to the sale of our common shares, no par value per common share, offered by this prospectus supplement. In accordance with the terms of the sales agreement, we may offer and sell from time to time our common shares having an aggregate offering price of up to US$75,000,000 through or to the Agents, each acting as sales agent or principal.
Eurotradr
3 years ago
ACST - Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan
Acasti Pharma, Inc.
Wed, October 6, 2021, 8:30 AM
Patents strengthen Acastiโs IP portfolio and provide protection through 2036 and 2037, respectively
LAVAL, Québec, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (โAcastiโ or the โCompanyโ) (Nasdaq: ACST and TSX-V: ACST), today announces that the European Patent Office, Chinese Patent Office and the Mexican Patent Office have issued composition of matter patents for GTX-101, a novel bio-adhesive film forming topical spray formulation of bupivacaine for the treatment of Postherpetic Neuralgia (PHN). PHN is a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years. GTX-101 could provide significant benefits over the current standard of care including greater convenience, faster onset of action and longer duration of pain relief. The granted patents are valid until 2036.
In addition, the Japanese Patent Office has granted a composition of matter patent for GTX-102, a novel, easy-to-use oral mucosal spray formulation of betamethasone, intended to improve neurological symptoms of Ataxia-telangiectasia (A-T). A-T is a progressive, neurodegenerative genetic disease that primarily affects children causing severe physical disability, for which no treatment currently exists. The granted patent is valid until 2037.
Jan DโAlvise, Chief Executive Officer of Acasti, stated, โThese latest patents are important additions to our intellectual property portfolio, expanding product protection to additional important international markets as we continue to progress these drug candidates through clinical studies. We believe these granted composition of matter patents further support the commercial potential of GTX-101 and GTX-102. Both drug candidates have already received Orphan Drug Designation from the FDA and could address important underserved global markets. The goal of these proprietary formulations is to improve the quality of care and patient outcomes by providing significant efficacy, safety and convenience benefits including ease of use, faster onset of action and extended relief.โ
https://finance.yahoo.com/news/acasti-pharma-awarded-composition-matter-123000390.html
georgie18
3 years ago
ACST/ACSTX...$30.40...1/8 Reverse Split...https://www.otcmarkets.com/filing/html?id=15192357&guid=iOP9kW-VfXy9sth
LAVAL, Québec, Aug. 27, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (โAcastiโ) (NASDAQ: ACSTโTSX-V: ACST), announced today the completion of its previously disclosed acquisition of Grace Therapeutics, Inc. (โGraceโ) via merger. The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases. Based on managementโs current forecasts, Acasti expects to have enough cash on its balance sheet following the merger to provide at least two years of operating runway. The combined companies will be led by Jan DโAlvise as President and Chief Executive Officer, under the oversight of Acastiโs newly elected Board of Directors, comprised of four re-elected directors of Acasti and two Grace nominees newly elected as directors (with a third Grace nominee expected to be nominated prior to the next annual meeting of shareholders). All Grace employees will transition to Acasti and they will continue to maintain a research and development laboratory and commercial presence in North Brunswick, New Jersey.
Eurotradr
3 years ago
"As part of the Acasti annual and special meeting, Acasti will be seeking the shareholder approvals necessary to complete the merger, elect directors and for other related matters. The 2021 annual and special meeting of Acasti shareholders will be held virtually on August 26, 2021, at 1:00 p.m. (Eastern Time), unless postponed or adjourned to a later date."